List view / Grid view
23 September 2015 | By Victoria White
In a Phase III study, significantly more patients who received Esbriet showed delayed progression of idiopathic pulmonary fibrosis (IPF) than those who received placebo...
21 September 2015 | By Roche
Roche announced that new Esbriet® (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 September 2015...
7 September 2015 | By Victoria White
The announcement follows a review that found that CDF spending would rise to around £410 million for this year - an over-spend of £70m from the budget set in April 2015...
4 September 2015 | By Victoria White
RoActemra has been recommended by NICE for the treatment of patients with severe rheumatoid arthritis whose disease has not responded to intensive therapy with a combination of cDMARDs...
4 September 2015 | By Victoria White
Breakthrough therapy designation has been granted to ACE910 for the prophylactic treatment of people with haemophilia A with factor VIII inhibitors...
27 August 2015 | By Nick Jackson
New treatment option for patients with difficult-to-treat form of skin cancer has shown improved treatment outcomes...
17 August 2015 | By Victoria White
In Roche’s large pivotal Phase II study, BIRCH, atezolizumab met its primary endpoint and shrank tumours in people with locally advanced or metastatic NSCLC...
13 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
Roche has announced the acquisition of GeneWEAVE BioSciences Inc. to strengthen its offering in the field of microbiology diagnostics.
12 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
Roche have announced positive results from the Phase II M13-982 study of venetoclax, an investigational medicine developed for hard-to-treat chronic lymphocytic leukaemia.
31 July 2015 | By Victoria White
Roche submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the FDA, as a companion diagnostic test for AZD9291...
31 July 2015 | By Victoria White
The EC has approved the use of Perjeta in combination with Herceptin and chemotherapy for use before surgery in patients with early stage breast cancer...
28 July 2015 | By Victoria White
Atezolizumab is poised to become a major bladder cancer therapy in the race for FDA approval, following its promising performance in recent Phase II trials...
13 July 2015 | By Victoria White
In the Phase II IMvigor 210 study, Roche’s atezolizumab shrank tumours in people with locally advanced or metastatic urothelial bladder cancer (UBC)...
2 July 2015 | By Victoria White
Evotec and Roche have provided an update on the initial results of the Phase IIb trial with Sembragiline for the treatment of Alzheimer's disease...
30 June 2015 | By Victoria White
Roche has announced positive results from two studies evaluating ocrelizumab compared with interferon beta-1a in people with relapsing multiple sclerosis...
